文献速递泌尿生殖与妇科肿瘤放疗

恩扎卢胺联合放疗治疗中危前列腺癌的2期研究

Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-23

这项开放标签2期研究评估了6个月恩扎卢胺单药联合外照射放疗治疗中危前列腺癌的疗效与安全性,主要终点为6个月时PSA缓解。64例患者中77%达到PSA≤0.2 ng/mL,94%达到PSA≤0.5 ng/mL,常见不良事件为高血压和男性乳房发育,体测指标无变化且勃起功能障碍轻微。

要点

  • 恩扎卢胺单药联合放疗在中危前列腺癌中显示较高PSA缓解率。
  • 常见不良事件为高血压和男性乳房发育,体测指标无变化。
  • 研究者认为需开展随机试验比较恩扎卢胺与ADT。

核心结论

  • 以PSA缓解为终点,恩扎卢胺单药联合外照射放疗对中危前列腺癌可能不劣于ADT联合放疗,且副作用更少。

研究设计与样本

  • 开放标签2期研究,样本量64例,恩扎卢胺单药治疗6个月,放疗前2个月开始用药,主要终点为6个月时PSA缓解。

主要发现

  • 64例中49例(77%)达到PSA≤0.2 ng/mL,60例(94%)达到PSA≤0.5 ng/mL。
  • 最常见不良事件为高血压和男性乳房发育,体测指标无变化,勃起功能障碍轻微。

关键数值与推荐

  • 预设假设:若≥60%的患者未达到PSA最低值≤0.2 ng/mL,则研究结果为阴性。
  • 实际64例中49例(77%)达到PSA≤0.2 ng/mL,60例(94%)达到PSA≤0.5 ng/mL。

临床怎么用

  • 恩扎卢胺单药联合放疗可作为中危前列腺癌ADT联合放疗的潜在替代方案,但需随机试验验证。

局限性

  • 为开放标签单臂2期研究,样本量64例,需随机试验比较恩扎卢胺与ADT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Androgen deprivation therapy (ADT) is often used as adjuvant treatment with radiation therapy (RT) for intermediate-risk prostate cancer. ADT is associated with multiple side effects, including weight gain, loss of libido, and hot flashes. In contrast, antiandrogen monotherapy has been generally better tolerated. This study aimed to assess the effectiveness of enzalutamide (an antiandrogen) monotherapy with RT for the treatment of intermediate-risk prostate cancer. METHODS AND MATERIALS: This trial was an open-label, phase 2 study of 6 months of enzalutamide monotherapy with external beam RT for intermediate-risk prostate cancer. Enzalutamide was initiated 2 months before external beam RT. The primary endpoint was prostate-specific antigen (PSA) response measured at the end of enzalutamide administration at the 6-month timepoint. Secondary endpoints included assessment of toxicity and changes in anthropomorphic body measurement, sexual function, and metabolism. The sample size was 64 patients. The hypothesis was that if ≥60% of the patients did not achieve a PSA nadir of ≤0.2 ng/mL, the study results would be deemed negative. RESULTS: The results met the prespecified endpoint for efficacy in that PSA values ≤0.2 ng/mL were observed in 49 of 64 patients (77%), and 60 of 64 patients (94%) had PSA values ≤0.5ng/mL. The most frequent adverse events were hypertension and gynecomastia. There were no changes in anthropomorphic body measurements and only modest erectile dysfunction. CONCLUSIONS: Using PSA response as an endpoint, enzalutamide monotherapy may be as effective as ADT in combination with external beam RT for patients with intermediate-risk prostate cancer, and it is associated with fewer side effects. Randomized trials comparing enzalutamide with ADT are justified.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kaplan I, Bubley GJ, Bhatt RS, et al. Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2021. PMID: 33636278. doi:10.1016/j.ijrobp.2021.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。